Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Sep 6;105(6):746-52.
doi: 10.1038/bjc.2011.310. Epub 2011 Aug 9.

How do patient and hospital features influence outcomes in small-cell lung cancer in England?

A L Rich  1 , L J Tata, C M Free, R A Stanley, M D Peake, D R Baldwin, R B Hubbard
Affiliations

How do patient and hospital features influence outcomes in small-cell lung cancer in England?

A L Rich et al. Br J Cancer. .

Abstract

Background: Our aim was to systematically determine how features of patients and hospitals influence access to chemotherapy and survival for people with small-cell lung cancer in England.

Methods: We linked the National Lung Cancer Audit and Hospital Episode Statistics and used multiple logistic and Cox regression analyses to assess the influence of patient and hospital features on small-cell lung cancer outcomes.

Results: There were 7845 patients with histologically proven small-cell lung cancer. Sixty-one percent (4820) of the patients received chemotherapy. Increasing age, worsening performance status, extensive stage and greater comorbidity all reduced the likelihood of receiving chemotherapy. There was wide variation in access to chemotherapy between hospitals in general and patients first seen in centres with a strong interest in clinical trials had a higher odds of receiving chemotherapy (adjusted odds ratio 1.42, 95% confidence interval (CI) 1.06, 1.90). Chemotherapy was associated with a lower mortality rate (adjusted hazard ratio 0.51, 95% CI 0.46, 0.56).

Conclusion: Patients first seen at a hospital with a keen interest in clinical trials are more likely to receive chemotherapy, and chemotherapy was associated with improved survival.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kaplan–Meier survival curve for patients with proven small-cell lung cancer based on receipt of chemotherapy (N=7782).
See this image and copyright information in PMC

References

    1. Asmis TR, Ding K, Seymour L, Shepherd FA, Leighl NB, Winton TL, Whitehead M, Spaans JN, Graham G B Goss CD (2008) Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials. J Clin Oncol 26(1): 54–59 - PubMed
    1. Brown JS, Eraut D, Trask C, Davison AG. (1996) Age and the treatment of lung cancer. Thorax 51(6): 564–568 - PMC - PubMed
    1. Campbell NC, Elliott AM, Sharp L, Ritchie LD, Cassidy J, Little J (2000) Rural factors and survival from cancer: analysis of Scottish cancer registrations. Br J Cancer 82(11): 1863–1866 - PMC - PubMed
    1. Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5): 373–383 - PubMed
    1. Coebergh JW, Janssen-Heijnen ML, Post PN, Razenberg PP (1999) Serious co-morbidity among unselected cancer patients newly diagnosed in the southeastern part of The Netherlands in 1993-1996. J Clin Epidemiol 52(12): 1131–1136 - PubMed

Publication types